



RETRACTED: Long Non-Coding RNA ELFN1-AS1 Promoted Colon Cancer Cell Growth and Migration via the miR-191-5p/Special AT-Rich Sequence-Binding Protein 1 Axis

OPEN ACCESS

Edited by:

Xiaochen Wang,
University of Texas Southwestern
Medical Center, United States

Reviewed by:

Jing Zhao,
Brigham and Women's Hospital and
Harvard Medical School, United States
Dongming Chen,
Nanjing Medical University, China

*Correspondence:

Tingxin Li
litingxin@med.uestc.edu.cn

†These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Cancer Genetics,
a section of the journal
Frontiers in Oncology

Received: 28 July 2020

Accepted: 09 November 2020

Published: 09 February 2021

Citation:

Du Y, Hou Y, Shi Y, Liu J and
Li T (2021) Long Non-Coding
RNA ELFN1-AS1 Promoted
Colon Cancer Cell Growth and
Migration via the miR-191-5p/
Special AT-Rich Sequence-
Binding Protein 1 Axis.
Front. Oncol. 10:588360.
doi: 10.3389/fonc.2020.588360

Yongjun Du^{1†}, Yanmei Hou^{1†}, Yongbo Shi^{2†}, Juan Liu³ and Tingxin Li^{4*}

¹ Department of Proctology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China, ² Department of Proctology, Zigong City Hospital of Traditional Chinese Medicine, Zigong City, China, ³ Huai'an Second People's Hospital and The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China, ⁴ Health Management Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China

Long non-coding RNAs (lncRNAs) are reported to participate in tumor development. It has been manifested in previous researches that lncRNA *ELFN1-AS1* is involved in early-stage colon adenocarcinoma with potential diagnostic value. However, no studies have revealed the specific mechanism of *ELFN1-AS1* in colon cancer, and there are no other studies on whether *ELFN1-AS1* is associated with tumorigenesis. In our study, *ELFN1-AS1* with high expression in colon cancer was selected by TCGA analysis, and the survival analysis was carried out to verify it. Subsequently, qRT-PCR was adopted for validating the results in tissues and cell lines. Cell counting kit-8 (CCK8), 5-ethynyl-2'-deoxyuridine (EdU), cell colon, cell apoptosis, cell cycle, cell migration, and invasion assays were utilized to assess the role of *ELFN1-AS1* in colon cancer. Results uncovered that *ELFN1-AS1* expression was prominently raised in colon cancer cells and tissues. *ELFN1-AS1* decrement restrained cells to grow through interfering with distribution of cell cycle and promoting apoptosis. Meanwhile, *ELFN1-AS1* decrement weakened the capacity of cells to migrate and invade. What's more, *ELFN1-AS1* was uncovered to act as a competing endogenous RNA (ceRNA) to decrease miR-191-5p expression, thus raising special AT-rich sequence-binding protein 1 (*SATB1*), a downstream target of ceRNA. To sum up, *ELFN1-AS1* drives colon cancer cells to proliferate and invade through adjusting the miR-191-5p/*SATB1* axis. The above results disclose that lncRNA *ELFN1-AS1* is possibly a novel treatment target for colon cancer cases.

Keywords: long non-coding RNA *ELFN1-AS1*, special AT-rich sequence-binding protein 1, colon cancer, ceRNA, miR-191-5p

INTRODUCTION

The American Cancer Society statistics manifest that colon cancer has a incidence rate of 10.2% and a death rate of 9.2% in human, ascending from the fourth place to the second (1, 2). Colon cancer cases at the early stage are generally treated by tumor resection, and the combined therapy with chemotherapeutic drugs is usually applied in colon cancer cases at different stages, especially at the late stage (3). These drugs include cytotoxic drugs (oxaliplatin, 5-fluorouracil, capecitabine and irinotecan) and biological agents (panitumumab, bevacizumab and cetuximab) (4, 5). In the beginning, the combined chemotherapy is useful in most colon cancer cases, but owing to drug resistance, the disease recurs in approximately 50% of the cases, with over 10% reduction in the five-year survival rate of late-stage cases (6, 7). Besides, liver metastasis arises at the time of first diagnosis in about 25% of colon cancer cases, and occurs within three years after first surgery in about 50% of them (8). Thus, investigation of the molecular mechanism of metastasis meets the clinical needs.

Long non-coding RNAs (lncRNAs) exert vital impacts in diversely adjusting gene expression, including chromatin modification as well as transcriptional and posttranscriptional processing (9). Aberrant modulation of lncRNAs usually induces tumor to form, grow and metastasize (10). For example, lncRNA *DLEU2* adjusts non-small cell lung cancer cells to proliferate and invade by controlling the miR-30c-5p/SOX9 axis (11). In addition, the elevated lncRNA *PANDAR* indicates poor prognosis and boosts cervical cancer cells to proliferate (12). LncRNA *ELFN1-AS1* promotes esophageal cancer progression by up-regulating *GFPT1* via sponging miR-183-3p (13). Meanwhile, *ELFN1-AS1* accelerates cell proliferation, invasion and migration via regulating miR-497-3p/*CLDN4* axis in ovarian cancer (14). What more, previous study has revealed that *ELFN1-AS1* is involved in early-stage colon adenocarcinoma with potential diagnostic value (15). However, no studies have revealed the specific mechanism by which *ELFN1-AS1* plays a role in colon cancer, and researches on whether *ELFN1-AS1* is linked to tumorigenesis are deficient.

MicroRNAs (miRNAs) are small ncRNAs that bind to the three prime untranslated region (3'-UTR) of downstream mRNAs and give rise to mRNA degradation or translation inhibition (16). The aberrant modulation of miRNAs commonly boosts cancers to form and develop (17). For example, the elevated miRNA-146a represses biological behaviors of ESCC by *IRS2* suppression (18). Besides, miR-146b-5p promotes papillary thyroid carcinoma cells to migrate

and invade (19). It has been identified that miR-191-5p restrains tumor in renal cell carcinoma (20) and colon adenocarcinoma (21), but whether miR-191-5p is co-regulated with *ELFN1-AS1* to regulate colon cancer is unknown.

In this research, lncRNA *ELFN1-AS1* expression level was identified to rise in colon cancer cells and tissues. The rising *ELFN1-AS1* facilitated colon cancer cells to grow, migrate and invade. What's more, *ELFN1-AS1* sponged miR-191-5p and played a biological role.

MATERIALS AND METHODS

Collection of Colon Cancer Samples and Culture of Colon Cancer Cells

Twenty pairs of colon cancer samples were collected from Huai'an Second People's Hospital and The Affiliated Huai'an Hospital of Xuzhou Medical University. All patients gave the written informed consent, and all assay regimens gained the approval of the Clinical Research Ethics Committees of Huai'an Second People's Hospital and The Affiliated Huai'an Hospital of Xuzhou Medical University.

The normal colonic epithelial cell line NCM460 and colon cancer cell lines (SW620, HT-29, HCT 116, LoVo, and SW480) were purchased from Cell Bank of Typical Culture Preservation Commission, Chinese academy of Sciences. Then they were cultured in a humid environment with 5% CO₂ at 37°C in RPMI-1640 containing 10% fetal bovine serum.

Real-Time PCR Assay, Transfection of Cells as Well as Production and Transduction of Lentiviruses

TRIzol reagent (Invitrogen) was utilized for total RNA extraction from colon cancer cells as per the guideline of the manufacturer. After that, the extracted RNA was subjected to reverse transcription into cDNA using the Reverse Transcription Kit from Takara. **Table 1** displays the applied primers.

MiR-191-5p, anti-miR-191-5p, miR-NC, and anti-miR-NC that were applied for cell transfection were synthesized by Ruibo (Guangzhou, China), and the plasmid pcDNA-3.1-special AT-rich sequence-binding protein 1 (SATB1) was provided by Santa Cruz. As per the guideline of the manufacturer, transfection with oligonucleotides was executed with the use of lipofectamine 2000 reagent from Invitrogen.

The aforementioned shRNAs sequences aiming for *ELFN1-AS1* underwent cloning into the pLKO.1 vector from Addgene as

TABLE 1 | Primers used in the study.

	Forward	Reverse
ELFN1-AS1	5'- AAAAGTTGACGCGCATTCT -3'	5'- GAGAATGGATTGTGGGTGCC-3'
miR-191-5p	5'-ACACTCCAGCTGGGCGACGAAAACCCUAA- 3'	5'- CTCAACTGGTGTGCGTGGAGTCGGCAATTCAGTTGAGTTCGGTTG -3'
U6	5'-CTCGCTTCGGCAGCACA-3'	5'-AACGCTTCACGAATTTGCGT-3'
SATB1	5'- GATCATTGAACGAGGCAACTCA-3'	5'- TGGACCCCTTCGGATCACTCA-3'
GAPDH	5'- TCGGAGTCAACGGATTTGGTCTG-3'	5'- TGCCATGGGTGGAATCATATTGGA-3

per the guideline of the manufacturer. Lentiviruses aiming for *ELFN1-AS1* (sh-*ELFN1-AS1*) and the empty lentiviral vector (sh-NC) were employed to co-infect cells together with 8µg/mL Polybrene for subsequent assays.

Cell Counting Kit-8 Assay and 5-ethynyl-2'-deoxyuridine Assay

In a 96-well plate, the cells treated in advance were inoculated and then incubated with CCK8 reagent provided by DingGuo Bio for 2 h at 37°C. Finally, a microplate reader provided by BioTek was employed to detect the absorbance (450 nm).

Next, EdU assay was executed with the use of Cell-Light EdU Cell Proliferation/DNA Kit acquired from Guangzhou RiboBio Co., Ltd. (China). In detail, the cells were immobilized with 4% paraformaldehyde and dyed with Apollo Dye Solution subsequent to EdU incubation for 2 h, followed by mounting with Hoechst 33342. Ultimately, photographing and quantification were carried out for EdU-positive cells.

Transwell Assay, Cell Cycle, and Apoptosis Assay

Cells were inoculated into the Transwell chambers undergoing 30 min of Matrigel coating at 37°C on the upper side, while 500 µl of complete medium into the bottom side. After 48 h, the cells on the bottom side were rinsed with PBS, immobilized in 4% paraformaldehyde and dyed with crystal violet solution. Ultimately, photos were taken under a microscope. Analysis for cells in each group was conducted thrice.

Next, the cells were trypsinized for separation, rinsed twice with forecooling PBS, and immobilized in 70% ethanol at -20°C nightlong. Following suspension in 100 µg/ml of RNaseA and 50 µg/ml of propidium iodide (PI) both provided by KeyGen BioTECH, the immobilized cells were suspended and incubated at room temperature for 40 min. Eventually, the cells were filtered, and flow cytometry was executed to detect the cell cycle.

For apoptosis assay, the cells were washed with PBS and then stained using the Annexin V-FITC Apoptosis Detection Kit (Affymetrix eBioscience) according to the instructions. Ultimately, the cells were analyzed with a FACS flow cytometer (BD Biosciences).

Western Blot Detection

RIPA lysis buffer provided by Thermo Scientific was utilized for protein separation from cells, and the protein concentration was measured using BCA Protein assay kit from Beyotime. Later, electrophoresis was carried out for proteins separation, and the separated proteins were transferred onto a PVDF membrane and blocked by skim milk (5%). Afterwards, SATB1 (Lot No. ab92307) and GAPDH (Lot No. ab9484) primary antibodies from Abcam were applied for membrane incubation nightlong at 4°C, and secondary antibodies conjugated with horseradish peroxidase were utilized for sealing the membrane at room temperature for 1 h. Ultimately, BioSpectrum 600 Imaging System from UVP (CA, USA) was adopted to obtain images. The selected concentration in this research was 1: 500.

RNA-Binding Protein Immunoprecipitation Experiment

In RIP experiment, the EZ-Magna RIP Kit used in the RIP assay was commercially acquired from Millipore (Billerica, MA, USA). After miR-191-5p or miR-NC transfection into cells, Ago2-RIP assays were executed. In the first place, the cells underwent lysis by RIP lysis buffer with RNase and proteinase inhibitors provided by Millipore. Secondly, the RIP lysates were subjected to RIP buffer, which contained magnetic beads conjugated with human anti-Ago2 antibody or nonspecific mouse IgG antibody (Millipore). Next, the immunoprecipitates were digested using proteinase K, and the gathering of *ELFN1-AS1* was examined using RT-PCR and gel staining. Ultimately, the RNA concentration was detected *via* a NanoDrop spectrophotometer, and q-RT-PCR analysis was conducted for the purified RNA.

Dual Luciferase Reporter Assay

Following amplification of the 3'-UTRs of SATB1 and *ELFN1-AS1*, they were independently cloned into the firefly luciferase gene downstream in the pGL3 vector from Promega, which was named as wild-type (WT) 3'-UTR. According to the detection using QuickChange site-directed mutagenesis kit from Stratagene (Cedar Creek, USA), there were mutant miR-191-5p binding sites in SATB1 3'-UTR, which was called MUT 3'-UTR. Colon cancer cells were transfected together with WT-3'-UTR or MUT-3'-UTR and miR-NC or miR-191-5p. Subsequent to 48 h of transfection, dual luciferase reporter assay system provided by Promega was employed for the luciferase assay. Analysis in each group was executed thrice.

Subcellular Distribution

The Cytoplasmic and Nuclear RNA Purification Kit (Norgen Biotek Corp.) was used to examine RNA degradation in the cytoplasm or nucleus. SW620 and HT-29 cells were lysed on ice for 5 min and then centrifuged at 12,000xg for 3 min. The supernatant was collected to examine RNAs originating in the cytoplasm, and the nuclear pellet was employed to extract RNAs from the nuclei. Total RNA in each fraction was quantified using RT-qPCR with U6 and GAPDH as internal references for the nucleus and cytoplasm, respectively.

Immunofluorescence Staining

After immobilization and sealing, tissues were incubated in antibody of SATB1 (Invitrogen, Carlsbad, California, USA) at 4°C for 24 h. After being washed, cells were incubated in FITC-labeled IgG (H+L) (Beyotime, Nantong, China) for 60 min. Later, DAPI was used for nucleus staining. The protocol was described in detail in the previous study (22).

Tumor Formation in the Body

BALB/c-nu/nu mice at the age of five weeks received subcutaneous seeding of 2×10^6 SW620 cells (sh-*ELFN1-AS1* or sh-NC) in the flank. Tumor volumes were determined every 7 days and calculated as $(\text{length} \times \text{width}^2)/2$. Twenty-eight days after subcutaneous injection, tumors were obtained and weighed following the execution of the mice. As per the US National Institute of Health Guidelines for Use of Experimental Animals,

the mice were maintained and received experiments in SPF Animal Laboratory at Xuzhou Medical University that were approved by the Ethnic Committee for Experimental Animals in Huai'an Second People's Hospital and The Affiliated Huai'an Hospital of Xuzhou Medical University.

Statistical Analysis

GraphPad Prism 6.0 software (GraphPad Software, Inc.) was used for statistical analyses. Experimental results are expressed as the mean \pm standard deviation (SD). The statistically significant differences between tumor tissues and adjacent normal tissues were determined using paired Student's *t*-test. The statistically significant differences between other two groups were determined using Mann-Whitney *U*-test or unpaired Student's *t*-test, where appropriate. The comparisons among different groups (multigroup comparisons) were analyzed by one-way ANOVA followed by the *post hoc* Bonferroni test. Log-rank test and Kaplan-Meier method were used to assess survival rates. $P < 0.05$ suggested a statistically significant difference.

RESULTS


LncRNA *ELFN1-AS1* Expression Level was Raised in Colon Cancer Cells and Tissues

Based on TCGA database analysis, *ELFN1-AS1* with a high expression in colon cancer was selected as a research object

(**Figure 1A**). RT-PCR was executed to inquire *ELFN1-AS1* expression level in the pairs of primary colon cancer tissues and non-tumor tissues. Results unraveled that colon cancer tissues expressed *ELFN1-AS1* at a markedly higher level than non-tumor colon tissues (**Figure 1B**). Similarly, colon cancer cells also expressed *ELFN1-AS1* at a notably higher level than NCM460 (**Figure 1C**). What's more, TCGA database analysis disclosed that raised *ELFN1-AS1* expression was related to short overall survival of colon cancer patients (**Figure 1D**).

Long Non-Coding RNA *ELFN1-AS1* Decrement Restrained Colon Cancer *In Vitro*

SW620 and HT-29 cells with the highest *ELFN1-AS1* expression level were established firstly, and their *ELFN1-AS1* was pulled down (**Figure 2A**). As the transfection efficiency of sh-*ELFN1-AS1*-1 is best, sh-*ELFN1-AS1*-1 was selected as sh-*ELFN1-AS1* for further studies. CCK-8 assay, EdU, cell colony-forming experiment disclosed that *ELFN1-AS1* decrement prominently curbed cells to proliferate (**Figures 2B-D**). Moreover, flow cytometry uncovered that the cell frequency in sh-*ELFN1-AS1* group was higher at G1 phase and lower at the S phase (**Figure 2E**). Later, whether lncRNA *ELFN1-AS1* exerted impacts on apoptosis was figured out using apoptosis analysis. Results corroborated that *ELFN1-AS1* decrement triggered colon cancer cell apoptosis (**Figure 3A**). Ultimately, Transwell assay







FIGURE 2 | LncRNA *ELFN1-AS1* decrease restrains colon cancer cell proliferation and cell cycle. (A) *ELFN1-AS1* expression in SW620 and HT-29 cells treated with sh-NC or *ELFN1-AS1* shRNAs. (B) CCK-8 assay, (C) EdU (bar = 100 μ m), and (D) cell colony-forming experiment were performed to test cell proliferation of SW620 and HT-29 cells. (E) sh-*ELFN1-AS1* cells show a remarkably lower frequency at S phase. Data are shown as the means \pm SEM of three experiments. ** $P < 0.01$, *** $P < 0.001$.

was executed to determine lncRNA *ELFN1-AS1*'s impacts on colon cancer cell migration and invasion. It was disclosed that *ELFN1-AS1* repression alleviated colon cancer cell migration and invasion (Figures 3B, C).

Mutual Inhibition Between Long Non-Coding RNA *ELFN1-AS1* and miR-191-5p Expression

lncRNA subcellular distribution determines the biological role (23). Colon cancer cells were separated into the cytoplasm and nuclear fractions to verify the *ELFN1-AS1* cellular location, with GAPDH and U6 as controls, respectively. RT-qPCR results revealed that *ELFN1-AS1* was mainly distributed in the cytoplasmic fraction of colon cancer cells (Figure 4A). MiRNAs with complementary base matching *ELFN1-AS1* was looked up using RegRNA 2.0 (<http://regRNA2.mbc.nctu.edu.tw/>),

among which emphasis was put on miR-191-5p, a recognized tumor-suppressing factor that restraining cancer cells to proliferate and invade (20, 21). Results manifested that relative to non-tumor colon tissues, miR-191-5p expression was decreased in colon cancer tissues (Figure 4B), and sh-*ELFN1-AS1* could significantly increase miR-191-5p levels in SW620 and HT-29 cells (Figure 4C). Besides, the binding sites between miR-191-5p and *ELFN1-AS1* were displayed in Figure 4D. Later, the speculated miR-191-5p binding site of *ELFN1-AS1* (*ELFN1-AS1*-WT) and a mutant miR-191-5p binding site of *ELFN1-AS1* (*ELFN1-AS1*-MUT) underwent cloning into reporter plasmids. Co-transfection with miR-191-5p and *ELFN1-AS1*-WT strongly weakened the luciferase activity, whereas co-transfection with miR-191-5p and *ELFN1-AS1*-MUT had no influence on the luciferase activity (Figure 4D). Then, whether miR-191-5p could negatively regulate *ELFN1-AS1* expression was tested. As



displayed in **Figure 4E**, cells receiving miR-191-5p treatment expressed *ELFN1-AS1* at a reduced level, but those receiving anti-miR-191-5p treatment expressed *ELFN1-AS1* at a raised level. Finally, RIP assays verified the gathering of miR-191-5p and *ELFN1-AS1* in Ago2 immunoprecipitates rather than control IgG immunoprecipitates (**Figure 4F**). Collectively, the above data imply that miR-191-5p is able to bind to *ELFN1-AS1* in a direct way and to inversely regulate *ELFN1-AS1* expression.

Special AT-Rich Sequence-Binding Protein 1 Was the Direct Target of miR-191-5p

MiRNAs function primarily by modulating the downstream targets of them (24, 25). Then, the target genes of miR-191-5p were looked up using Targetscan 7.2 (http://www.targetscan.org/vert_72/, top ten genes) and miRDB (<http://mirdb.org/>, score \geq 85). As shown in the **Figure 5A**, four target genes were found. Then, we detected the expression of these four genes (*NEURL4*, *TAF5*, *TMOD2*, and *SATB1*). We found that only the expression of *SATB1* was downregulated after miR-191-5p mimics transfection in SW620 cells (**Figure 5B**). Thus, *SATB1* was selected from the speculated target genes of miR-191-5p for later research. It was manifested by luciferase assay that the luciferase activities in SW620 and HT-29 cells receiving co-transfection with miR-191-5p and WT-*SATB1*-3'-UTR were

weakened relative to other groups (**Figure 5C**). *SATB1* expression level in colon cancer tissues was also detected. Western blot assay validated that *SATB1* expression was elevated in colon cancer tissues relative to non-tumor colon tissues (**Figure 5D**). Immunofluorescence staining showed the same results (**Figure 5E**). Besides, miR-191-5p restrained *SATB1* protein to be expressed in SW620 and HT-29 cells (**Figure 5F**). In sh-*ELFN1-AS1* cells, the level of *SATB1* was discovered to be lower than that in sh-NC cells. Nevertheless, anti-miR-191-5p treatment restored *SATB1* in sh-*ELFN1-AS1* cells (**Figure 5G**). In all, the above data suggest that the *SATB1* is a downstream target gene of miR-191-5p and modulated by *ELFN1-AS1*.

Long Non-Coding RNA *ELFN1-AS1* Decrement Impeded Tumor to Grow in the Body

Whether *ELFN1-AS1* decrement impeded tumor to grow in the body was explored. It was disclosed that the growth of SW620 cells was slower in the case of lncRNA *ELFN1-AS1* repression (**Figure 6A**). The average weight and volume of xenograft tumors in sh-*ELFN1-AS1* group were less than those in sh-NC group (**Figures 6B, C**). Later, lncRNA *ELFN1-AS1* expression in the resected tumor tissues was examined. Results unraveled that sh-*ELFN1-AS1* group had decreased *ELFN1-AS1* expression




FIGURE 4 | Mutual repression between lncRNA *ELFN1-AS1* and miR-191-5p. **(A)** Cytoplasmic and nuclear levels of *ELFN1-AS1* in colon cancer cells assessed by RT-qPCR. **(B)** qRT-PCR assay reveals the miR-191-5p level in colon cancer tissues. **(C)** sh-*ELFN1-AS1* cells express miR-191-5p at a higher level than sh-NC cells. **(D)** The binding sites between miR-191-5p on *ELFN1-AS1*. And dual luciferase reporter assay was performed to verify binding relationship of miR-191-5p and *ELFN1-AS1*. **(E)** miR-191-5p inversely modulates *ELFN1-AS1* expression. **(F)** *ELFN1-AS1* and miR-191-5p gather in Ago2 immunoprecipitates compared with control IgG immunoprecipitates. Data are shown as the means \pm SEM of three experiments.

** $P < 0.01$, *** $P < 0.001$.

relative to sh-NC group (Figure 6D). Lastly, staining was executed for tumor sections to detect SATB1 expression, and it was disclosed that SATB1 expression was expressed at a lower level in sh-*ELFN1-AS1* group (Figure 6E). To sum up, it can be inferred that *ELFN1-AS1* boosts the tumor to grow in the body.

Long Non-Coding RNA *ELFN1-AS1* Regulated Colon Cancer Cell Proliferation, Invasion, Apoptosis, and Cycle Through miR-191-5p/SATB1 Axis

To verify the function of *ELFN1-AS1*/miR-191-5p/SATB1 in colon cancer, rescue experiments were carried out for

SW620 and HT-29 cells. SW620 (sh-*ELFN1-AS1*) and HT-29 (sh-*ELFN1-AS1*) cells stably transfected with sh-*ELFN1-AS1* were cultured and divided into 3 groups and transfected with NC, anti-miR-191-5p, and pcDNA-SATB1, respectively. The results of CCK-8 and EdU experiments showed that the proliferation abilities of anti-miR-191-5p group and pcDNA-SATB1 group were significantly increased (Figures 7A, B). In addition, anti-miR-191-5p and pcDNA-SATB1 also enhanced the invasive abilities of SW620 (sh-*ELFN1-AS1*) and HT-29 (sh-*ELFN1-AS1*) cells (Figure 7C), but inhibited G1 arrest (Figure 7D) and apoptosis (Figure 7E) of colon cancer cells.




FIGURE 5 | miR-191-5p/SATB1 axis mediates *ELFN1-AS1*'s impacts on cell growth and invasion. **(A)** Bioinformatics analysis with miRDB and TargetScan 7.2. **(B)** The expression of the predictive target genes after miR-191-5p mimics transfection in SW620 cells. **(C)** The binding sites between miR-191-5p and SATB1. Dual luciferase assay uncovers that co-transfection with miR-191-5p and SATB1-WT evidently weakens the luciferase activity. **(D)** SATB1 protein expression rises in colon cancer tissues relative to normal tissues. C, cancer tissues; N, normal tissues. **(E)** Western blot assay discloses that colon cancer tissues express SATB1 at an elevated level than normal tissues. **(F)** miR-191-5p represses SATB1 protein expression in colon cancer cells. **(G)** Anti-miR-191-5p treatment gives rise to the restoration of SATB1 in sh-*ELFN1-AS1* cells. Data are shown as the means \pm SEM of three experiments. ** $P < 0.01$. *** $P < 0.001$, ns, no significance.




FIGURE 6 | *ELFN1-AS1* inhibition curbs the tumor to grow in the body. **(A)** Xenograft tumors. **(B)** The growth of xenograft tumors from sh-*ELFN1-AS1* cells is slower than that of xenograft tumors from sh-NC cells. **(C)** The mean weight of xenograft tumors. **(D)** *ELFN1-AS1* expression in xenograft tumors is determined. **(E)** *ELFN1-AS1* decrement pronouncedly reduces SATB1 in tumors compared with negative control group. **** $P < 0.001$.




FIGURE 7 | LncRNA *ELFN1-AS1* modulates colon cancer cell proliferation, invasion, cell cycle, and cell apoptosis through miR-191-5p/SATB1 axis. **(A)** CCK-8 assay and **(B)** EdU assay reveal that anti-miR-191-5p and pcDNA-SATB1 promote cell proliferation in SW620 (sh-*ELFN1-AS1*) and HT-29 (sh-*ELFN1-AS1*) cells (bar = 100 μ m). **(C)** Cell invasion assay in SW620 (sh-*ELFN1-AS1*) and HT-29 (sh-*ELFN1-AS1*) cells (bar = 100 μ m). **(D)** Cell cycle assay in SW620 and HT-29 cells stably transfected with sh-*ELFN1-AS1*. **(E)** Cell apoptosis assay in SW620 and HT-29 cells stably transfected with sh-*ELFN1-AS1*. Data are shown as the means \pm SEM of three experiments. ** $P < 0.01$, *** $P < 0.001$.

DISCUSSION

Colon cancer ranks third among the most common cancers globally, and it is the second most frequently seen cause of death correlated with cancer (26). At present, prior to the development of new and effective treatment methods for colon cancer, there is a need to figure out the possible mechanisms by which colon cancer develops and progresses. Recently, lncRNAs have been indicated to exert pivotal effects in the development of different tumors, including colon cancer (27). TCGA data were used to analyze lncRNAs associated with colon cancer, high-expression *ELFN1-AS1* was selected as a research object and validated in population tissues and cells.

Functional assays unraveled that repression of *ELFN1-AS1* restrained SW620 and HT-29 cells to proliferate, migrate, and invade. Besides, *ELFN1-AS1* was disclosed to boost the G1-S phase transition of cell cycle and likely to protect SW620 and HT-29 cells from apoptosis. The abovementioned findings imply that *ELFN1-AS1* is an oncogene and it facilitates the formation of colon cancer.

SATB1 is a nuclear matrix-correlated protein involved in chromatin organization with a higher order and in modulating

the expression of tissue-specific genes (28). It has been manifested that SATB1 is related to the development of different cancers, including oral squamous cell carcinoma (29), colorectal cancer (30), bladder cancer (31), and prostate cancer (32). Nonetheless, it has been reported that SATB1 decrement restrains breast cancer cells to proliferate, grow and invade by modulating gene expression (33). In this research, stably reducing *ELFN1-AS1* expression pronouncedly attenuated the abilities of colon cancer cells to proliferate and invade, which could be reversed by SATB1 overexpression.

This research has several deficiencies. First, a larger sample size is required to further explore the clinical value of *ELFN1-AS1*. Second, more target genes or miRNAs should be applied to interact with *ELFN1-AS1*. Third, more different mouse models need be used to further verify our conclusion.

In conclusion, *ELFN1-AS1* is prominently raised in colon cancer tissues and cell lines. Furthermore *ELFN1-AS1* could promote proliferation and migration of colon cancer cells through miR-191-5p/SATB1 axis.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The Affiliated Huai'an Hospital of Xuzhou Medical University. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by The Affiliated Huai'an Hospital of Xuzhou Medical University.

REFERENCES

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* (2018) 68(6):394–424. doi: 10.3322/caac.21492
- Wen J, Min X, Shen M, Hua Q, Han Y, Zhao L, et al. ACLY facilitates colon cancer cell metastasis by CTNNB1. *J Exp Clin Cancer Res* (2019) 38(1):401. doi: 10.1186/s13046-019-1391-9
- Tamas K, Walenkamp AM, de Vries EG, van Vugt MA, Beets-Tan RG, van Etten B, et al. Rectal and colon cancer: Not just a different anatomic site. *Cancer Treat Rev* (2015) 41(8):671–9. doi: 10.1016/j.ctrv.2015.06.007
- Banerjee A, Pathak S, Subramaniam VD, Dharanivasan D, Murugesan R, Verma RS. Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives. *Drug Discovery Today* (2017) 22(8):1224–32. doi: 10.1016/j.drudis.2017.05.006
- Cartwright TH. Treatment decisions after diagnosis of metastatic colorectal cancer. *Clin Colorectal Cancer* (2012) 11(3):155–66. doi: 10.1016/j.clcc.2011.11.001
- Meyers BM, Cosby R, Queresby F, Jonker D. Adjuvant Chemotherapy for Stage II and III Colon Cancer Following Complete Resection: A Cancer Care Ontario Systematic Review. *Clin Oncol (R Coll Radiol)* (2017) 29(7):459–65. doi: 10.1016/j.clon.2017.03.001
- Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barz A, et al. Colorectal cancer statistics, 2017. *CA Cancer J Clin* (2017) 67(3):177–93. doi: 10.3322/caac.21395
- Rosen AW, Degett TH, Gogenur I. [Individualized treatment of colon cancer]. *Ugeskr Laeger* (2016) 178(31).
- Sun Q, Hao Q, Prasanth KV. Nuclear Long Noncoding RNAs: Key Regulators of Gene Expression. *Trends Genet* (2018) 34(2):142–57. doi: 10.1016/j.tig.2017.11.005
- Sun W, Yang Y, Xu C, Guo J. Regulatory mechanisms of long noncoding RNAs on gene expression in cancers. *Cancer Genet* (2017) 216–217:105–10. doi: 10.1016/j.cancergen.2017.06.003
- Zhou Y, Shi H, Du Y, Zhao G, Wang X, Li Q, et al. lncRNA DLEU2 modulates cell proliferation and invasion of non-small cell lung cancer by regulating miR-30c-5p/SOX9 axis. *Aging (Albany NY)* (2019) 11(18):7386–401. doi: 10.18632/aging.102226
- Huang HW, Xie H, Ma X, Zhao F, Gao Y. Upregulation of lncRNA PANDAR predicts poor prognosis and promotes cell proliferation in cervical cancer. *Eur Rev Med Pharmacol Sci* (2017) 21(20):4529–35.
- Zhang C, Lian H, Xie L, Yin N, Cui Y. LncRNA ELFN1-AS1 promotes esophageal cancer progression by up-regulating GFPT1 via sponging miR-183-3p. *Biol Chem* (2020) 401(9):1053–61. doi: 10.1515/hsz-2019-0430
- Jie Y, Ye L, Chen H, Yu X, Cai L, He W, et al. ELFN1-AS1 accelerates cell proliferation, invasion and migration via regulating miR-497-3p/CLDN4 axis in ovarian cancer. *Bioengineered* (2020) 11(1):872–82. doi: 10.1080/21655979.2020.1797281
- Liu JX, Li W, Li JT, Liu F, Zhou L. Screening key long non-coding RNAs in early-stage colon adenocarcinoma by RNA-sequencing. *Epigenomics* (2018) 10(9):1215–28. doi: 10.2217/epi-2017-0155
- Tutar Y. miRNA and cancer; computational and experimental approaches. *Curr Pharm Biotechnol* (2014) 15(5):429. doi: 10.2174/138920101505140828161335
- Zagryazhskaya A, Zhivotovsky B. miRNAs in lung cancer: a link to aging. *Ageing Res Rev* (2014) 17:54–67. doi: 10.1016/j.arr.2014.02.009
- Liu H, Ren G, Zhu L, Liu X, He X. The upregulation of miRNA-146a inhibited biological behaviors of ESCC through inhibition of IRS2. *Tumour Biol* (2016) 37(4):4641–7. doi: 10.1007/s13277-015-4274-5
- Lima CR, Geraldo MV, Fujiwara CS, Kimura ET, Santos MF. MiRNA-146b-5p upregulates migration and invasion of different Papillary Thyroid Carcinoma cells. *BMC Cancer* (2016) 16:108. doi: 10.1186/s12885-016-2146-z
- Chen P, Pan X, Zhao L, Jin L, Lin C, Quan J, et al. MicroRNA-191-5p exerts a tumor suppressive role in renal cell carcinoma. *Exp Ther Med* (2018) 15(2):1686–93. doi: 10.3892/etm.2017.5581
- Chen XY, Zhang J, Hou LD, Zhang R, Chen W, Fan HN, et al. Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma. *Int J Immunopathol Pharmacol* (2018) 32:2058738418790318. doi: 10.1177/2058738418790318
- Min X, Wen J, Zhao L, Wang K, Li Q, Huang G, et al. Role of hepatoma-derived growth factor in promoting de novo lipogenesis and tumorigenesis in hepatocellular carcinoma. *Mol Oncol* (2018) 12(9):1480–97. doi: 10.1002/1878-0261.12357
- Miao H, Wang L, Zhan H, Dai J, Chang Y, Wu F, et al. A long noncoding RNA distributed in both nucleus and cytoplasm operates in the PYCARD-regulated apoptosis by coordinating the epigenetic and translational regulation. *PLoS Genet* (2019) 15(5):e1008144. doi: 10.1371/journal.pgen.1008144
- Bhaskaran M, Mohan M. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. *Vet Pathol* (2014) 51(4):759–74. doi: 10.1177/0300985813502820
- Roberts JT, Borchert GM. Computational Prediction of MicroRNA Target Genes, Target Prediction Databases, and Web Resources. *Methods Mol Biol* (2017) 1617:109–22. doi: 10.1007/978-1-4939-7046-9_8
- Cheng Y, Zhu Y, Xu J, Yang M, Chen P, Xu W, et al. PKN2 in colon cancer cells inhibits M2 phenotype polarization of tumor-associated macrophages via regulating DUSP6-Erk1/2 pathway. *Mol Cancer* (2018) 17(1):13. doi: 10.1186/s12943-017-0747-z
- Wu Q, Meng WY, Jie Y, Zhao H. LncRNA MALAT1 induces colon cancer development by regulating miR-129-5p/HMGB1 axis. *J Cell Physiol* (2018) 233(9):6750–7. doi: 10.1002/jcp.26383
- Nakayama Y, Mian IS, Kohwi-Shigematsu T, Ogawa T. A nuclear targeting determinant for SATB1, a genome organizer in the T cell lineage. *Cell Cycle* (2005) 4(8):1099–106. doi: 10.4161/cc.4.8.1862
- Li YC, Bu LL, Mao L, Ma SR, Liu JF, Yu GT, et al. SATB1 promotes tumor metastasis and invasiveness in oral squamous cell carcinoma. *Oral Dis* (2017) 23(2):247–54. doi: 10.1111/odi.12602

AUTHOR CONTRIBUTIONS

YD and TL performed the experiments and prepared the manuscript. YH and YS collected and analyzed the data. YH supported the administration and technique, and provided the materials. JL and TL designed and supervised the study, and revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by The National Key R&D Program of China (No.2017YFC0113901 granted to Liu Yuping).

30. Brocato J, Costa M. SATB1 and 2 in colorectal cancer. *Carcinogenesis* (2015) 36(2):186–91. doi: 10.1093/carcin/bgu322
31. Choudhary D, Clement JM, Choudhary S, Voznesensky O, Pilbeam CC, Woolbright BL, et al. SATB1 and bladder cancer: Is there a functional link? *Urol Oncol* (2018) 36(3):93 e13–21. doi: 10.1016/j.urolonc.2017.10.004
32. Mao LJ, Yang CH, Fan L, Gao P, Yang DR, Xue BX, et al. SATB1 promotes prostate cancer metastasis by the regulation of epithelial-mesenchymal transition. *BioMed Pharmacother* (2016) 79:1–8. doi: 10.1016/j.biopha.2016.01.038
33. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. *Nature* (2008) 452(7184):187–93. doi: 10.1038/nature06781

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Du, Hou, Shi, Liu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

RETRACTED